Clinical Trials Browser

INDUSTRY × Everolimus × 1 year × Clear all

Neoplasm Metastasis

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Carcinoma, Renal Cell

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Carcinoma, Renal Cell

Breast Neoplasms, Recurrence

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Seizures, Tuberous Sclerosis

Tuberous Sclerosis, Angiomyolipoma

Breast Neoplasms

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Breast Neoplasms

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Solid Tumors

Breast Neoplasms

Breast Neoplasms

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors

Breast Neoplasms, Endometrial Neoplasms

Neuroendocrine Tumors

Carcinoma, Hepatocellular

Carcinoma, Renal Cell, Kidney Neoplasms

Carcinoma, Renal Cell

Clinical Trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

ADONIS

STELLAR-311

CLEAR

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

MK-6482-043

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Sapu003 in Advanced mTOR-sensitive Solid Tumors

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

ACTION-1

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

ELEVATE

LITESPARK-029

AMEERA-1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

TACTIVE-E

A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

COMPOSE

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

EMBER

COMPETE

Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma